article thumbnail

DCAT Week 2025: Key Takeaways & Industry Advancements

Frost & Sullivan

With 87% of biopharma manufacturers targeting renewable electricity by 2030, CDMOs must align with evolving sustainability regulations and partner expectations. trillion in 2024, is expected to grow at a 7% CAGR through 2030.